I have been on Attruby ( acaromadis ) since Febuary . Attruby was FDA appoved in November and has a better success rate than Vyndamax (tafamadis). Attruby stabilizes the misfolded proteins in the liver so they be flushed out of your system . I was accepted in the CRISPR-Cas9 trial and will be receiving my infusion this coming Tuesday. The Cas9 enzyme is a protein that acts like molecular scissors, targeting the misfolded proteins in the liver and cuts(edits) the DNA , thus correcting the faulty gene. The cells natural DNA repairs the cut strands. This is a one time infusion to stop the liver from creating the proteins and will be revolutionary in treating ATTR-CM.
Amvuttra is a quarterly injection designed to reduce the amount of misfolded proteins created in the liver. It DOES NOT eliminate the production of the misfolded proteins. As a result I chose to patricipate in the clinical trial . Best of Luck